PARP1 and ovarian carcinoma: For example, the SOLO3 trial which evaluated the PARP inhibitor, olaparib as a single agent against non-platinum based single agent chemotherapy in patients with BRCA mutated platinum sensitive recurrent ovarian cancer, the subgroup who had received only 2 prior lines of treatment had an ORR of 85%.15 Cognizant of the selection bias of phase II trials, phase III trials remain the true benchmark for defining standard of care.